AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 182 min read$TNYA

Ali Faraz sold $16K of TNYA

Ali Faraz (Chief Executive Officer) sold 22,232 shares of Tenaya Therapeutics, Inc. (TNYA) at an average of $0.71 ($0.71–$0.71) across 4 trades on 2026-08-17.

Original reporting
SEC EDGAR · Ali Faraz
Published Aug 18, 2026, 12:50 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 1:05 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$TNYA
Neutral
medium confidence
Mentioned
$TNYA
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TNYANeutralLow
01

Why it matters

This is a disclosed insider sale by the CEO, which may affect sentiment but does not change fundamentals based on the provided text.

02

Market read

Traders may monitor for follow-on insider activity or any concurrent company-specific catalysts, but the filing alone is not a fundamental update.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without volume/price reaction data or a broader pattern, the signal is weak.

Relevance 3/10Novelty 4/10Timing: filed for an Aug. 17 insider sale, available pre-market Aug. 18

Background

The article is a SEC Form 4 insider transaction disclosure for Tenaya Therapeutics, Inc.

Company-level read

Ticker impact

$TNYANeutralMedium confidence
Context

CEO Ali Faraz sold about 22,232 shares of Tenaya Therapeutics at roughly $0.7097 to $0.7098 per share via open-market transactions.

Expected impact

Likely limited near-term impact; treat as routine insider liquidity unless corroborated by other company-specific news.

Evidence & confidence

Form 4 insider sales are common and the article provides no accompanying rationale, 10b5-1 plan, or new company catalyst beyond the transaction details.

Market effects

Sector

No clear sector read-through from a single CEO open-market sale without additional clinical, regulatory, or financing context.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the CEO sale was not explicitly tied to a 10b5-1 plan in the text, some traders may interpret it as a mild negative signal, especially for a microcap.

Key entities

  • issuer
    Tenaya Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Ali Faraz

    CEO and director who sold shares in open-market transactions.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TNYA insider trading history →

Related articles

AUG 18
$TNYAMed

Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301

Tenaya Therapeutics (NASDAQ:TNYA) said it plans Q4 updates for gene therapy TN-401 in PKP2-associated ARVC, with early data showing ~60% to 67% PVC reductions across patients (up to 52 weeks). It also reported Phase 1 results for TN-301 (72 patients) and Phase 2-enabling work. Tenaya had ~$78M cash and a $10M upfront Alnylam deal.

yahoo.com5 min
AUG 5
$TNYAMed

Tenaya Therapeutics, Inc. (TNYA): Results of Operations and Financial Condition

Tenaya Therapeutics, Inc. (TNYA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tnya-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements

SEC EDGAR 8-K6 min
JUN 3
$TNYAMedAI 9/10

Tenaya's TN-201 Gene Therapy Shows Sustained Cardiac Improvements In MYBPC3-Associated HCM

Tenaya Therapeutics reported interim MyPEAK-1 Phase 1b/2 data for TN-201, an investigational gene therapy for MYBPC3-associated hypertrophic cardiomyopathy. As of a May 2026 cutoff, six evaluable patients showed improvements in echocardiographic hypertrophy and symptom measures; three improved exercise capacity. Company said benefits were sustained up to two years in Cohort 1 and earlier in Cohort 2. PRIME and FDA rare disease processes apply.

rttnews.com4 min
AUG 18
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $6.1M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 246,568 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $24.85 ($24.69–$24.87, $6.13M total) across 3 trades over 2026-08-13 to 2026-08-17. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Divisadero Street Capital, LLC (10% owner), Divisadero Street Partners, L.P. (10% owner) and Zolezzi William (10% owner).

SEC EDGAR2 min